Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms

Blood Cells, Molecules, and Diseases

Volumn 47, Issue 1, 2011, Pages 67-71

  Chen, Xiuhua ^a   Qi, Xiling ^a   Tan, Yanhong ^a   Xu, Zhifang ^a   Xu, Aining ^a   Zhang, Linlin ^a   Wang, Hongwei ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

JAK2V617F; MPL exon10; MPLW515 mutations; Myeloproliferative neoplasms

Indexed keywords

GENOMIC DNA; THROMBOPOIETIN RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOPOIETIN RECEPTOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CHINA; EXONS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; RECEPTORS, THROMBOPOIETIN; YOUNG ADULT;

EID: 79956300828     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2011.04.004     Document Type: Article

References (21)

1. Levine R.L., Pardananh A., Tefferi A., Gilliland D.G. Role of JAK2 in pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 2007, 7:673-683.
2. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005, 434:1144-1148.
3. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
4. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
5. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352:1779-1790.
6. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 2005, 280:22788-22792.
7. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107:4274-4281.
8. Lacout C., Pisani D.F., Tulliez M., Gachelin F.M., Vainchenker W., Villeval J.L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006, 108:1652-1660.
9. Pardanani A.D., Levine R.L., Lasho T., et al. MPLW515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
10. Liu K., Martini M., Rocca B., et al. Evidence for a founder effect of the MPL-S505N mutation in 8 Italian pedigrees with hereditary thrombocythemia. Haematologica 2009, 94:1368-1374.
11. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006, 3(7):e270.
12. Schnittger S., Bacher U., Haferlach C., Beelen D., Bojko P., Bürkle D., et al. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica 2009, 94(1):141-144.
13. Tefferi A., Thiele J., Vardiman J.W. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009, 115:3842-3847.
14. Scott L.M., Campbell P.J., Baxter E.J., Todd T., Stephens P., et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005, 106:2920-2921.
15. Parganas E., Wang D., Stravopodis D., Topham D.J., Marine J.C., Teglund S., et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93:385-395.
16. Beer P.A., Campbell P.J., Scott L.M., Bench A.J., Erber W.N., Bareford D., et al. MPL mutations in myeloproliferative disorders: analyses of the PT-1 cohort. Blood 2008, 112:141-149.
17. de la Chapelle A., Traskelin A.L., Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc. Natl Acad. Sci. U. S. A. 1993, 90:4495-4499.
18. Ding J., Komatsu H., Wakita A., Kato-Uranishi M., Ito M., Satoh A., et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004, 103:4198-4200.
19. Chaligné R., Tonetti C., Besancenot R., Roy L., Marty C., Mossuz P., et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G(1)/S-phase transition. Leukemia 2008, 22(8):1557-1566.
20. Vannucchi A.M., Antonioli E., Guglielmelli P., Pancrazzi A., Guerini V., Barosi G., et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008, 112:844-847.
21. Basquiera Ana L., Fassetta Fernanda, Soria Néstor, Barral José Moreno, Brenda Ricchi, García Juan J. Accuracy of leukocyte alkaline phosphatase score to predict JAK2 V617F mutation. Haematologica 2007, 92:704-705.